These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23704979)

  • 1. EGFR, FLT1 and heparanase as markers identifying patients at risk of short survival in cholangiocarcinoma.
    Hoffmann AC; Goekkurt E; Danenberg PV; Lehmann S; Ehninger G; Aust DE; Stoehlmacher-Williams J
    PLoS One; 2013; 8(5):e64186. PubMed ID: 23704979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
    Andersen JB; Spee B; Blechacz BR; Avital I; Komuta M; Barbour A; Conner EA; Gillen MC; Roskams T; Roberts LR; Factor VM; Thorgeirsson SS
    Gastroenterology; 2012 Apr; 142(4):1021-1031.e15. PubMed ID: 22178589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trefoil factors: tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma.
    Kosriwong K; Menheniott TR; Giraud AS; Jearanaikoon P; Sripa B; Limpaiboon T
    World J Gastroenterol; 2011 Mar; 17(12):1631-41. PubMed ID: 21472131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-mobility group box 1 expression and lymph node metastasis in intrahepatic cholangiocarcinoma.
    Xu YF; Ge FJ; Han B; Yang XQ; Su H; Zhao AC; Zhao MH; Yang YB; Yang J
    World J Gastroenterol; 2015 Mar; 21(11):3256-65. PubMed ID: 25805932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of NQO1 expression in intrahepatic cholangiocarcinoma.
    Wakai T; Shirai Y; Sakata J; Matsuda Y; Korita PV; Takamura M; Ajioka Y; Hatakeyama K
    Int J Clin Exp Pathol; 2011 Apr; 4(4):363-70. PubMed ID: 21577322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A metabolism-related 4-lncRNA prognostic signature and corresponding mechanisms in intrahepatic cholangiocarcinoma.
    Zou W; Wang Z; Wang F; Li L; Liu R; Hu M
    BMC Cancer; 2021 May; 21(1):608. PubMed ID: 34034689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.
    Xu L; Hausmann M; Dietmaier W; Kellermeier S; Pesch T; Stieber-Gunckel M; Lippert E; Klebl F; Rogler G
    BMC Cancer; 2010 Jun; 10():302. PubMed ID: 20565817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High expression of matrix metalloproteinase-9 indicates poor prognosis in human hilar cholangiocarcinoma.
    Sun Q; Zhao C; Xia L; He Z; Lu Z; Liu C; Jia M; Wang J; Niu J
    Int J Clin Exp Pathol; 2014; 7(9):6157-64. PubMed ID: 25337264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.
    Yoshikawa D; Ojima H; Iwasaki M; Hiraoka N; Kosuge T; Kasai S; Hirohashi S; Shibata T
    Br J Cancer; 2008 Jan; 98(2):418-25. PubMed ID: 18087285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression.
    Lu D; Han C; Wu T
    Gastroenterology; 2011 Jun; 140(7):2084-94. PubMed ID: 21354147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA in intrahepatic cholangiocarcinoma.
    Morine Y; Shimada M; Utsunomiya T; Imura S; Ikemoto T; Hanaka J; Kanamoto M; Kurita N; Miyake H
    Surg Today; 2012 Jan; 42(2):135-40. PubMed ID: 22143355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic potential of cyclin kinase subunit-2 in cholangiocarcinoma.
    Shen DY; Zhan YH; Wang QM; Rui G; Zhang ZM
    Liver Int; 2013 Jan; 33(1):137-48. PubMed ID: 23121546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOX4 is associated with poor prognosis in cholangiocarcinoma.
    Wang W; Zhang J; Zhan X; Lin T; Yang M; Hu J; Han B; Hu S
    Biochem Biophys Res Commun; 2014 Sep; 452(3):614-21. PubMed ID: 25181339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of C-met Expression in Cholangiocarcinoma.
    Mao ZY; Zhu GQ; Ren L; Guo XC; Su D; Bai L
    Technol Cancer Res Treat; 2016 Apr; 15(2):227-33. PubMed ID: 25873560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients.
    Gao Q; Zhao YJ; Wang XY; Guo WJ; Gao S; Wei L; Shi JY; Shi GM; Wang ZC; Zhang YN; Shi YH; Ding J; Ding ZB; Ke AW; Dai Z; Wu FZ; Wang H; Qiu ZP; Chen ZA; Zhang ZF; Qiu SJ; Zhou J; He XH; Fan J
    Gastroenterology; 2014 May; 146(5):1397-407. PubMed ID: 24503127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
    Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
    Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma.
    Boonjaraspinyo S; Boonmars T; Wu Z; Loilome W; Sithithaworn P; Nagano I; Pinlaor S; Yongvanit P; Nielsen PS; Pairojkul C; Khuntikeo N
    Tumour Biol; 2012 Oct; 33(5):1785-802. PubMed ID: 22733151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma.
    Maeda T; Taguchi K; Aishima S; Shimada M; Hintz D; Larusso N; Gores G; Tsuneyoshi M; Sugimachi K; Wands JR; de la Monte SM
    Cancer Detect Prev; 2004; 28(5):313-8. PubMed ID: 15542253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of EGFR family gene aberrations in cholangiocarcinoma.
    Yang X; Wang W; Wang C; Wang L; Yang M; Qi M; Su H; Sun X; Liu Z; Zhang J; Qin X; Han B
    Oncol Rep; 2014 Aug; 32(2):700-8. PubMed ID: 24927194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel prognostic biomarker for cholangiocarcinoma: circRNA Cdr1as.
    Jiang XM; Li ZL; Li JL; Xu Y; Leng KM; Cui YF; Sun DJ
    Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):365-371. PubMed ID: 29424892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.